World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 16 December 2017
Main ID:  NCT01191749
Date of registration: 27/08/2010
Prospective Registration: No
Primary sponsor: M.D. Anderson Cancer Center
Public title: Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)
Scientific title: Phase II Pilot Study Of Alemtuzumab In Patients With Low Or INT-1 Risk Myelodysplastic Syndrome (MDS), Aplastic Anemia (AA), Or T-Cell Large Granular Lymphocytic Leukemia (T-LGL)
Date of first enrolment: August 2010
Target sample size: 7
Recruitment status: Terminated
URL:  https://clinicaltrials.gov/show/NCT01191749
Study type:  Interventional
Study design:  Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  Phase 2
Countries of recruitment
United States
Contacts
Name:     Tapan Kadia, MD
Address: 
Telephone:
Email:
Affiliation:  UT MD Anderson Cancer Center
Key inclusion & exclusion criteria

Inclusion Criteria:

1. Patients with the diagnosis of MDS (Low, Int-1 by IPSS, or hypocellular) who are
either previously untreated or who have been previously treated are eligible for this
trial.

2. Patients with the diagnosis of aplastic anemia who have or have not been previously
treated are eligible for inclusion if they are not currently candidates for an
allogeneic stem cell transplant.

3. Patients with the diagnosis of T-LGL who have or have not been previously treated are
eligible for inclusion.

4. Patients must have been off of cytotoxic, immunosuppressive, or targeted therapy
(except hydroxyurea) for at least 2 weeks prior to entering this study, and have
recovered from the toxic effects of that therapy to grade 1 or less.

5. Adequate organ function as defined: liver function (bilirubin < or = 2mg/dL, AST
and/or ALT < or = 3 x ULN) ; kidney function (creatinine < or = 2.5 x ULN ).

6. ECOG performance status of < or = 3.

7. The effects of alemtuzumab on the developing human fetus are unknown. For this reason,
women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry and for
the duration of study participation. Should a woman become pregnant or suspect she is
pregnant while participating in this study, she should inform her treating physician
immediately.

8. A negative urine pregnancy test is required within 1 week for all women of
childbearing potential prior to enrolling on this trial.

9. Patient must have the ability to understand the requirements of the study and signed
informed consent. A signed informed consent by the patient or his legally authorized
representative is required prior to their enrollment on the protocol.

10. Patients should have an indication for therapy for their disease such as transfusion
dependence or morbidity associated with their cytopenia(s) such as bleeding, severe
fatigue, or frequent/multiple infections (eg. neutropenia).

Exclusion Criteria:

1. Pregnant women are excluded from this study because alemtuzumab is an agent with the
potential for teratogenic or abortifacient effects. Because there is an unknown but
potential risk for adverse events in nursing infants secondary to treatment of the
mother with alemtuzumab, breastfeeding should be discontinued if the mother is treated
with alemtuzumab. These potential risks may also apply to other agents used in this
study.

2. Known HIV infection.

3. Known Hepatitis B or Hepatitis C infection.

4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

5. Patient with documented hypersensitivity to alemtuzumab.



Age minimum: N/A
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Leukemia
Intervention(s)
Drug: Alemtuzumab
Primary Outcome(s)
Overall Response - Number of Participants Who Achieved Complete Remission (CR)+Partial Remission (PR) - as Per International Working Group (IWG) Response Criteria [Time Frame: Up to 6 months following treatment; response assessed every 2 months]
Secondary Outcome(s)
Secondary ID(s)
2010-0187
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available: Yes
Date Posted: 09/05/2017
Date Completed:
URL: https://clinicaltrials.gov/ct2/show/results/NCT01191749
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history